Allovir Inc expected to post a loss of 81  cents a share - Earnings Preview

Kalaris Therapeutics

07/02/2022 13:39

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results on February 9
(estimated). 
    * ​Refinitiv's mean analyst estimate for Allovir Inc is for
a loss
of 81 cents per share. For the same quarter last year, the
company reported a loss of 34 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$34​, about 76.4% above​ its last closing price of $8.04. ​​​
    * 

This summary was machine generated February 7 at 13:39 GMT.  All
figures in US dollars  unless otherwise stated